Korean scholars suggested that there were no significant differences between a poor CYP2C19 genotype for clopidogrel metabolism and a good CYP2C19 genotype in the rates of stroke recurrence, major vascular events for the secondary prevention of stroke [21]. This evidence concerns the gene CYP2C19 and stroke disorder.